Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2066 Compared to Placebo in Peripheral Neuropathic Pain Patients With Mechanical Hypersensitivity

NCT00939094 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00939094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00939094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2066 Compared to Placebo in Peripheral Neuropathic Pain Patients With Mechanical Hypersensitivity
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2009
Completion date
November 30, 2010
Enrollment
87 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

mechanical hypersensitivity, neuropathic pain